2013 marks a milestone year for plasmid DNA vaccine development as a first-in-class cytomegalovirus (CMV) DNA vaccine enters pivotal phase 3 testing. This vaccine consists of two plasmids expressing CMV antigens glycoprotein B (gB) and phosphoprotein 65 (pp65) formulated with a CRL1005 poloxamer and benzalkonium chloride (BAK) delivery system designed to enhance plasmid expression. The vaccine’s planned initial indication under investigation is for prevention of CMV reactivation in CMV-seropositive (CMV +) recipients of an allogeneic hematopoietic stem cell transplant (HCT). A randomized, double-blind placebo-controlled phase 2 proof-of-concept study provided initial evidence of the safety of this product in CMV + HCT recipients who underwent immune ablation conditioning regimens. This study revealed a significant reduction in viral load endpoints and increased frequencies of pp65-specific interferon-γ-producing T cells in vaccine recipients compared to placebo recipients. The results of this endpoint-defining trial provided the basis for defining the primary and secondary endpoints of a global phase 3 trial in HCT recipients. A case study is presented here describing the development history of this vaccine from product concept to initiation of the phase 3 trial.
References
[1]
Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247, 1465–1468.
[2]
Tang, D.C.; DeVit, M.; Johnston, S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356, 152–154, doi:10.1038/356152a0.
[3]
Ulmer, J.B.; Donnelly, J.J.; Parker, S.E.; Rhodes, G.H.; Felgner, P.L.; Dwarki, V.J.; Gromkowski, S.H.; Deck, R.R.; DeWitt, C.M.; Friedman, A.; et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745–1749.
[4]
MacGregor, R.R.; Boyer, J.D.; Ugen, K.E.; Lacy, K.E.; Gluckman, S.J.; Bagarazzi, M.L.; Chattergoon, M.A.; Baine, Y.; Higgins, T.J.; Ciccarelli, R.B.; et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J. Infect. Dis. 1998, 178, 92–100, doi:10.1086/515613.
[5]
Calarota, S.; Bratt, G.; Nordlund, S.; Hinkula, J.; Leandersson, A.C.; Sandstrom, E.; Wahren, B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351, 1320–1325, doi:10.1016/S0140-6736(97)09440-3.
[6]
Wang, R.; Doolan, D.L.; Le, T.P.; Hedstrom, R.C.; Coonan, K.M.; Charoenvit, Y.; Jones, T.R.; Hobart, P.; Margalith, M.; Ng, J.; et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282, 476–480, doi:10.1126/science.282.5388.476.
[7]
Liu, M.A. DNA vaccines: An historical perspective and view to the future. Immunol. Rev. 2011, 239, 62–84, doi:10.1111/j.1600-065X.2010.00980.x.
[8]
Ferraro, B.; Morrow, M.P.; Hutnick, N.A.; Shin, T.H.; Lucke, C.E.; Weiner, D.B. Clinical applications of DNA vaccines: Current progress. Clin. Infect. Dis. 2011, 53, 296–302, doi:10.1093/cid/cir334.
[9]
Boeckh, M.; Geballe, A.P. Cytomegalovirus: Pathogen, paradigm, and puzzle. J. Clin. Invest. 2011, 121, 1673–1680, doi:10.1172/JCI45449.
Staras, S.A.; Dollard, S.C.; Radford, K.W.; Flanders, W.D.; Pass, R.F.; Cannon, M.J. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin. Infect. Dis. 2006, 43, 1143–1151, doi:10.1086/508173.
[12]
Marty, F.M.; Ljungman, P.; Papanicolaou, G.A.; Winston, D.J.; Chemaly, R.F.; Strasfeld, L.; Young, J.A.; Rodriguez, T.; Maertens, J.; Schmitt, M.; et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 2011, 11, 284–292, doi:10.1016/S1473-3099(11)70024-X.
[13]
Pass, R.F.; Zhang, C.; Evans, A.; Simpson, T.; Andrews, W.; Huang, M. L.; Corey, L.; Hill, J.; Davis, E.; Flanigan, C.; et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 2009, 360, 1191–1199, doi:10.1056/NEJMoa0804749.
[14]
Griffiths, P.D.; Stanton, A.; McCarrell, E.; Smith, C.; Osman, M.; Harber, M.; Davenport, A.; Jones, G.; Wheeler, D.C.; O’Beirne, J.; et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 2011, 377, 1256–1263, doi:10.1016/S0140-6736(11)60136-0.
[15]
Bernstein, D.I.; Schleiss, M.R.; Berencsi, K.; Gonczol, E.; Dickey, M.; Khoury, P.; Cadoz, M.; Meric, C.; Zahradnik, J.; Duliege, A.M.; et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis. 2002, 185, 686–690, doi:10.1086/339003.
[16]
Berencsi, K.; Gyulai, Z.; Gonczol, E.; Pincus, S.; Cox, W.I.; Michelson, S.; Kari, L.; Meric, C.; Cadoz, M.; Zahradnik, J.; et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis. 2001, 183, 1171–1179, doi:10.1086/319680.
[17]
Bernstein, D.I.; Reap, E.A.; Katen, K.; Watson, A.; Smith, K.; Norberg, P.; Olmsted, R.A.; Hoeper, A.; Morris, J.; Negri, S.; et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28, 484–493, doi:10.1016/j.vaccine.2009.09.135.
Junghanss, C.; Storb, R.; Maris, M.B.; Carter, R.A.; Sandmaier, B.M.; Maloney, D.G.; McSweeney, P.A.; Corey, L.; Boeckh, M. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br. J. Haematol. 2003, 123, 662–670, doi:10.1046/j.1365-2141.2003.04671.x.
[20]
Gyulai, Z.; Endresz, V.; Burian, K.; Pincus, S.; Toldy, J.; Cox, W.I.; Meric, C.; Plotkin, S.; Gonczol, E.; Berencsi, K. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: Reevaluation of prevalence of IE1-specific CTLs. J. Infect. Dis. 2000, 181, 1537–1546, doi:10.1086/315445.
[21]
Kern, F.; Bunde, T.; Faulhaber, N.; Kiecker, F.; Khatamzas, E.; Rudawski, I.M.; Pruss, A.; Gratama, J.W.; Volkmer-Engert, R.; Ewert, R.; et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 2002, 185, 1709–1716, doi:10.1086/340637.
[22]
Britt, W.J.; Vugler, L.; Butfiloski, E.J.; Stephens, E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 1990, 64, 1079–1085.
[23]
Sylwester, A.W.; Mitchell, B.L.; Edgar, J.B.; Taormina, C.; Pelte, C.; Ruchti, F.; Sleath, P.R.; Grabstein, K.H.; Hosken, N.A.; Kern, F.; et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202, 673–685, doi:10.1084/jem.20050882.
[24]
Walter, E.A.; Greenberg, P.D.; Gilbert, M.J.; Finch, R.J.; Watanabe, K.S.; Thomas, E.D.; Riddell, S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl J. Med. 1995, 333, 1038–1044, doi:10.1056/NEJM199510193331603.
[25]
Peggs, K.S.; Verfuerth, S.; Pizzey, A.; Khan, N.; Guiver, M.; Moss, P.A.; Mackinnon, S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362, 1375–1377, doi:10.1016/S0140-6736(03)14634-X.
[26]
Einsele, H.; Roosnek, E.; Rufer, N.; Sinzger, C.; Riegler, S.; Loffler, J.; Grigoleit, U.; Moris, A.; Rammensee, H.G.; Kanz, L.; et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99, 3916–3922, doi:10.1182/blood.V99.11.3916.
[27]
Einsele, H.; Kapp, M.; Grigoleit, G.U. CMV-specific T cell therapy. Blood Cells Mol. Dis. 2008, 40, 71–75, doi:10.1016/j.bcmd.2007.07.002.
[28]
Selinsky, C.; Luke, C.; Wloch, M.; Geall, A.; Hermanson, G.; Kaslow, D.; Evans, T. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum. Vaccine Immunother. 2005, 1, 16–23.
[29]
Endresz, V.; Kari, L.; Berencsi, K.; Kari, C.; Gyulai, Z.; Jeney, C.; Pincus, S.; Rodeck, U.; Meric, C.; Plotkin, S.A.; et al. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 1999, 17, 50–58, doi:10.1016/S0264-410X(98)00145-5.
[30]
Yao, Z.Q.; Gallez-Hawkins, G.; Lomeli, N.A.; Li, X.; Molinder, K.M.; Diamond, D.J.; Zaia, J.A. Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting. Vaccine 2001, 19, 1628–1635, doi:10.1016/S0264-410X(00)00423-0.
[31]
Triozzi, P.L.; Stevens, V.C.; Aldrich, W.; Powell, J.; Todd, C.W.; Newman, M.J. Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer. Clin. Cancer Res. 1997, 3, 2355–2362.
[32]
Casimiro, D.R.; Chen, L.; Fu, T.M.; Evans, R.K.; Caulfield, M.J.; Davies, M.E.; Tang, A.; Chen, M.; Huang, L.; Harris, V.; et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 2003, 77, 6305–6313.
Evans, R.K. Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines. J. Pharm. Sci. 2004, 93, 1924–1939.
[35]
Inactive Ingredient Search for Approved Drug Products. Available online: http://www.accessdata.fda.gov/ (accessed on 12 April 2013).
[36]
Hartikka, J.; Geall, A.; Bozoukova, V.; Kurniadi, D.; Rusalov, D.; Enas, J.; Yi, J.H.; Nanci, A.; Rolland, A. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J. Gene Med. 2008, 10, 770–782, doi:10.1002/jgm.1199.
[37]
Mahajan, R.; Feher, B.; Jones, B.; Jones, D.; Marjerison, L.; Sam, M.; Hartikka, J.; Wloch, M.; Lalor, P.; Kaslow, D.; et al. A TaqMan reverse transcription polymerase chain reaction (RT-PCR) in vitro potency assay for plasmid-based vaccine products. Mol. Biotechnol. 2008, 40, 47–57, doi:10.1007/s12033-008-9058-3.
[38]
Wloch, M.K.; Smith, L.R.; Boutsaboualoy, S.; Reyes, L.; Han, C.; Kehler, J.; Smith, H.D.; Selk, L.; Nakamura, R.; Brown, J.M.; et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis. 2008, 19, 1634–1642.
[39]
Kharfan-Dabaja, M.A.; Boeckh, M.; Wilck, M.B.; Langston, A.A.; Chu, A.H.; Wloch, M.K.; Guterwill, D.F.; Smith, L.R.; Rolland, A.P.; Kenney, R.T. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 2012, 12, 290–299, doi:10.1016/S1473-3099(11)70344-9.
Go, V.; Pollard, R.B. A cytomegalovirus vaccine for transplantation: Are we closer? J. Infect. Dis. 2008, 19, 1631–1633.
[42]
Adler, S.P. Human CMV vaccine trials: What if CMV caused a rash? J. Clin. Virol. 2008, 41, 231–623, doi:10.1016/j.jcv.2007.11.008.
[43]
Public Workshop—The Development and Evaluation of Human Cytomegalovirus Vaccines. Available online: http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm280016.htm (accessed on 23 August 2013).
[44]
Hartikka, J.; Bozoukova, V.; Morrow, J.; Rusalov, D.; Shlapobersky, M.; Wei, Q.; Boutsaboualoy, S.; Ye, M.; Wloch, M.K.; Doukas, J.; et al. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum. Vaccine Immunother. 2012, 8, 1595–1606, doi:10.4161/hv.21225.
